Nektar Therapeutics (LON:0UNL)
London flag London · Delayed Price · Currency is GBP · Price in USD
51.28
+1.66 (3.35%)
At close: Sep 17, 2025

Nektar Therapeutics Revenue

Nektar Therapeutics had revenue of $11.18M USD in the quarter ending June 30, 2025, a decrease of -52.42%. This brings the company's revenue in the last twelve months to $74.93M, down -19.56% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.

Revenue (ttm)
$74.93M
Revenue Growth
-19.56%
P/S Ratio
12.71
Revenue / Employee
$1.23M
Employees
61
Market Cap
695.26M GBP

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202498.43M8.31M9.22%
Dec 31, 202390.12M-1.93M-2.10%
Dec 31, 202292.06M-9.85M-9.67%
Dec 31, 2021101.91M-51.01M-33.36%
Dec 31, 2020152.92M38.30M33.41%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
AstraZeneca41.24B
GSK plc31.63B
Haleon11.02B
Smith & Nephew4.33B
ConvaTec Group1.72B
Hikma Pharmaceuticals2.35B
HUTCHMED (China)439.54M
Genus672.80M
Revenue Rankings